MLL Rearrangement clinical trials at UCSF
1 research study open to eligible people
MLL rearrangement involves a swap of genetic material, contributing to some leukemia cases. UCSF is evaluating ziftomenib combinations for safety in those with relapsed acute myeloid leukemia. The trials are investigating whether this drug combination is well-tolerated and effective for patients.
Showing trials for
Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
open to eligible people ages 18 years and up
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
San Francisco, California and other locations
Last updated: